Ушбу иш иқтибос қилган ишлар

27 та иш

Иш: Catumaxomab

1. Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients

   Peter Ruf, Michael Kluge, Michael Jäger +7

   Мақола20103 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.913630

2. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody

   Peter Ruf, Horst Lindhofer

   Мақола20013 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.913633

3. Effective Relief of Malignant Ascites in Patients with Advanced Ovarian Cancer by a Trifunctional Anti-EpCAM × Anti-CD3 Antibody: A Phase I/II Study

   Alexander Burges, Pauline Wimberger, Carolin Kümper +15

   Мақола20073 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.913648

4. Simultaneous Activation of T Cells and Accessory Cells by a New Class of Intact Bispecific Antibody Results in Efficient Tumor Cell Killing

   Reinhard Zeidler, G. Reisbach, Barbara Wollenberg +4

   Мақола19992 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.913629

5. Pattern and prognostic factors in patients with malignant ascites: a retrospective study

   Abraham Ayantunde, SL Parsons

   Мақола20072 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.913645

6. Lysis of Prostate Carcinoma Cells by Trifunctional Bispecific Antibodies (αEpCAM × αCD3)

   Rainer Riesenberg, Alexander Büchner, Heike Pohla +1

   Мақола20012 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.913646

7. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells

   Reinhard Zeidler, Josef Mysliwietz, M Csanády +5

   Мақола20002 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.913701

8. Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer

   Peter Ruf, Olivier Gires, Michael Jäger +3

   Мақола20072 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.913704

9. Immunomonitoring Results of a Phase II/III Study of Malignant Ascites Patients Treated with the Trifunctional Antibody Catumaxomab (Anti-EpCAM × Anti-CD3)

   Michael Jäger, A. Schoberth, Peter Ruf +8

   Мақола20112 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.913705

10. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

    M. M. Heiss, P. Murawa, P. Koralewski +17

    Мақола20102 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.913710

11. Humoral response to catumaxomab correlates with clinical outcome: Results of the pivotal phase II/III study in patients with malignant ascites

    Marion Ott, Frederik Marmé, Gerhard Moldenhauer +6

    Мақола20112 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.913711

12. Catumaxomab

    R. Linke, Anke Klein, Diane Seimetz

    Шарҳ мақолаIntraperitoneal and Appendiceal MalignanciesmAbs20101 иқтибос

    ABIABI:AkademIndex/openalex/2010.review-article.000002

13. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.913699

14. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.913700

15. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.913702

16. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.913703

17. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.913706

18. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.913707

19. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.913708

20. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.913709

21. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.913712

22. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.913713

23. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.913714

24. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.913715

25. Сарлавҳасиз

    Бошқа1 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.913716